Baidu
map

JCEM:氨基酸和脂肪酸水平对健康人群肝脏磷代谢产物含量的影响

2017-11-15 MedSci MedSci原创

众所周知肝脏能量代谢与2型糖尿病患者的胰岛素抵抗与肝脏脂肪含量呈负相关,但是其在代谢健康人群中的作用还不清楚。

众所周知肝脏能量代谢与2型糖尿病患者的胰岛素抵抗和肝脏脂肪含量呈负相关,但是其在代谢健康人群中的作用还不清楚。

近日在JCEM上发表的一篇文章假设肝细胞内γ-三磷酸腺苷(γATP)和无机膦酸(PI)的浓度在非糖尿病非肥胖受试者中与胰岛素敏感有类似的关系。该研究共纳入76例受试者,进行了4点75gOGTT以及体内31P/1H磁共振波谱。其中62例进行了针对性的血浆代谢谱分析。对相关变量γATP和pi进行皮尔森相关分析。

研究结果显示,在调整了年龄、性别和BMI之后,肝γATP和PI与2hOGTT血糖相关(r=0.25和r=0.27,两者p<0.05),而且PI进一步与非酯化脂肪酸有关(r=0.28,p<0.05)。但是,无论是γATP还是PI都与胰岛素敏感性的一些测量不显著相关。肝γATP与循环亮氨酸有关(r=0.42,P<0.001)、PI与C16:1脂肪酸棕榈酸和C16:1w5(分别r=0.28和0.3,p<0.01)及δ- 9-去饱和酶指数(r=0.33,p<0.05)有关。在多因素校正后,只有γATP和亮氨酸的相关性显着。亮氨酸和棕榈酸,连同年龄、性别和BMI分别占γATP和PI变化的26%和15%。

由上述研究可以发现特定的循环氨基酸和非酯化脂肪酸而不是胰岛素的敏感性在一定程度上影响肝脏的磷代谢,提示非糖尿病患者中肝脏能量代谢和循环代谢的相互作用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1911114, encodeId=a2c81911114c3, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Tue Apr 03 03:37:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860841, encodeId=b757186084176, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Sep 07 07:37:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063083, encodeId=5c692063083cf, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 25 11:37:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777701, encodeId=28da1e777011d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Oct 22 08:37:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513447, encodeId=df3f151344e24, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Nov 17 06:37:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261494, encodeId=352926149445, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Nov 15 16:13:57 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1911114, encodeId=a2c81911114c3, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Tue Apr 03 03:37:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860841, encodeId=b757186084176, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Sep 07 07:37:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063083, encodeId=5c692063083cf, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 25 11:37:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777701, encodeId=28da1e777011d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Oct 22 08:37:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513447, encodeId=df3f151344e24, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Nov 17 06:37:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261494, encodeId=352926149445, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Nov 15 16:13:57 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1911114, encodeId=a2c81911114c3, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Tue Apr 03 03:37:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860841, encodeId=b757186084176, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Sep 07 07:37:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063083, encodeId=5c692063083cf, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 25 11:37:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777701, encodeId=28da1e777011d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Oct 22 08:37:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513447, encodeId=df3f151344e24, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Nov 17 06:37:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261494, encodeId=352926149445, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Nov 15 16:13:57 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
    2018-10-25 achengzhao
  4. [GetPortalCommentsPageByObjectIdResponse(id=1911114, encodeId=a2c81911114c3, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Tue Apr 03 03:37:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860841, encodeId=b757186084176, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Sep 07 07:37:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063083, encodeId=5c692063083cf, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 25 11:37:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777701, encodeId=28da1e777011d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Oct 22 08:37:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513447, encodeId=df3f151344e24, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Nov 17 06:37:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261494, encodeId=352926149445, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Nov 15 16:13:57 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
    2018-10-22 smallant2015
  5. [GetPortalCommentsPageByObjectIdResponse(id=1911114, encodeId=a2c81911114c3, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Tue Apr 03 03:37:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860841, encodeId=b757186084176, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Sep 07 07:37:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063083, encodeId=5c692063083cf, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 25 11:37:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777701, encodeId=28da1e777011d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Oct 22 08:37:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513447, encodeId=df3f151344e24, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Nov 17 06:37:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261494, encodeId=352926149445, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Nov 15 16:13:57 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1911114, encodeId=a2c81911114c3, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Tue Apr 03 03:37:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860841, encodeId=b757186084176, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Sep 07 07:37:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063083, encodeId=5c692063083cf, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Oct 25 11:37:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777701, encodeId=28da1e777011d, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Oct 22 08:37:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513447, encodeId=df3f151344e24, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Nov 17 06:37:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=261494, encodeId=352926149445, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Nov 15 16:13:57 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
    2017-11-15 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

Lancet Respir Med:儿科ICU:早期补充性肠外营养有害 哪种宏量营养素是罪魁祸首?

大型随机对照试验已经证明,入住成人和儿科重症监护病房(PICUs)患者早期补充肠外营养是有害的。但是,哪种宏量营养素是有害的原因,有待进一步证实。2017年5月,发表在《Lancet Respir Med》的一项研究显示,早期给予氨基酸可能为原因所在。

Chem Commun:用于抗癌疗法的一种有效氨基酸!

光动力疗法通常用于治疗脑肿瘤,因为它具有特异性——它可以靶向含有癌细胞的非常小的区域,同时使其周围的正常细胞免受损伤。它通过将称为光敏剂的药物注射到血液中,其中它聚集在细胞中,然后将药物填充的细胞暴露于光。当光敏剂暴露在这种光下时,它会释放所谓的导致细胞死亡的活性氧(ROS)。该方法是精确的,因为光敏剂优先聚集在癌细胞中。因此,当它们暴露于光时,正常的细胞将免受损害。

Hepatology:非酒精性脂肪肝患者中氨基酸水平影响肥胖和胰岛素抵抗

在非酒精性脂肪性肝病(NAFLD)中,经常发现氨基酸(AA),特别是支链(BCAA)的血浆浓度增加。然而,这一现象是否是由于增加的肌肉蛋白质分解代谢,肥胖和/或胰岛素抵抗(IR)增加或是由于受损的组织代谢导致的仍然尚未可知。针对这一问题,近期,一项发表在杂志Hepatology上的研究评估了a)与肥胖的NAFLD者(NAFLD-Ob)相比,非肥胖NAFLD(NAFLD-NO)的受试者与对照组(CT

MOL METAB:为什么吃肉等高蛋白食物顶饱?科学家首次揭示氨基酸直接作用下丘脑特殊细胞产生饱腹感的机制

据说,《超能陆战队》里胖胖的大白,在意识到肥胖对健康的危害后,下定决心准备好好减肥。经过一段时间的体育锻炼,终于甩掉了身上的肥肉,但是却变成了米其林轮胎人。痛定思痛之后,大白终于明白还是少吃点比较靠谱。但是,对于广大吃货来说,想让他们少吃点,谈何容易。庆幸的是,科学家们从未放弃拯救你“根本停不下来的食欲”和“越来越多的赘肉”。9 月 27 日,最新一期的《分子代谢》杂志发表了英国华威大学生命科学学

SCI REP:青春期女孩闲暇时间体力活动与循环氨基酸之间相关性分析!

在青春期的女孩中,高水平体力活动与血清异亮氨酸和亮氨酸较低水平相关,并且独立于BMI,这种相关性可作为儿童时期身体活动水平较高与之后生活的健康受益之间的一种机制性联系。需要在青春期男孩中进行进一步的研究以评估儿童的体力活动和青少年循环中氨基酸之间的相关性是否具有性别差异。

CHEM COMMUN:一种抗癌有效的氨基酸!

光动力疗法通常用于治疗脑肿瘤,因为它具有特异性——它可以靶向含有癌细胞的非常小的区域,同时使其周围的正常细胞免受损伤。它通过将称为光敏剂的药物注射到血液中,其中它聚集在细胞中,然后将药物填充的细胞暴露于光。当光敏剂暴露在这种光下时,它会释放所谓的导致细胞死亡的活性氧(ROS)。该方法是精确的,因为光敏剂优先聚集在癌细胞中。因此,当它们暴露于光时,正常的细胞将免受损害。

Baidu
map
Baidu
map
Baidu
map